Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Lambda-1a ± daclatasvir vs peginterferon alfa-2a plus ribavirin in treatment-naive genotype 2/3 chronic hepatitis C
2011-004885-14Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of peginterferon lambda-1a in chronic hepatitis C (CHC) and hepatitis C virus infection (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: SVR12. Started May 2012; status: completed.
02
Drugs
peginterferon lambda-1a
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2011-004885-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004885-14.